Drug
Mifepristone Korlym
Mifepristone Korlym: highest development phase Post-Market, developed by Corcept Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Corcept Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Mifepristone 300 MG [Korlym] NCT05772169 | Post-Market | Hypercortisolism |
Latest
No recent events.
Follow Mifepristone Korlym on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.